Bridging the gap between the north and south of the world: the case of treatment response in childhood acute lymphoblastic leukemia.
作者信息
Stanulla Martin, Schrauder André
出版信息
Haematologica. 2009 Jun;94(6):748-52. doi: 10.3324/haematol.2009.006783.
Abstract
摘要
相似文献
1
Bridging the gap between the north and south of the world: the case of treatment response in childhood acute lymphoblastic leukemia.
Haematologica. 2009 Jun;94(6):748-52. doi: 10.3324/haematol.2009.006783.
2
Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.
Haematologica. 2009 Jun;94(6):870-4. doi: 10.3324/haematol.2008.000414. Epub 2009 Apr 18.
3
Your dilemma, my identity: unusual immunogenetic profiles of pediatric B cell acute lymphoblastic leukemia.
Indian J Pathol Microbiol. 2014 Jan-Mar;57(1):78-80. doi: 10.4103/0377-4929.130904.
4
A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
Haematologica. 2009 Jun;94(6):781-9. doi: 10.3324/haematol.2008.003137.
5
Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Cytometry B Clin Cytom. 2013 Nov-Dec;84(6):359-69. doi: 10.1002/cyto.b.21101. Epub 2013 Jun 26.
6
Automated detection of residual leukemic cells by consecutive immunolabeling for CD10 and fluorescence in situ hybridization for ETV6/RUNX1 rearrangement in childhood acute lymphoblastic leukemia.
Cancer Genet Cytogenet. 2007 Feb;173(1):23-30. doi: 10.1016/j.cancergencyto.2006.09.007.
7
How I investigate minimal residual disease in acute lymphoblastic leukemia.
Int J Lab Hematol. 2021 Jun;43(3):354-363. doi: 10.1111/ijlh.13463. Epub 2021 Jan 10.
8
[Technical scheme of minimal residual disease detection with Ig/TCR rearrangements as molecular targets in childhood acute lymphoblastic leukemia].
Zhonghua Er Ke Za Zhi. 2011 Mar;49(3):165-9.
9
10
Detection of aneuploid cells in acute lymphoblastic leukemia with flow cytometry before and after therapy.
Leuk Res. 1994 Dec;18(12):897-901. doi: 10.1016/0145-2126(94)90101-5.
引用本文的文献
1
Low Prevalence of Fusion Gene in a Hispanic Population.
Front Pediatr. 2022 May 24;10:837656. doi: 10.3389/fped.2022.837656. eCollection 2022.
2
Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.
Mediterr J Hematol Infect Dis. 2016 Apr 10;8(1):e2016024. doi: 10.4084/MJHID.2016.024. eCollection 2016.
3
Qualitative polymerase chain reaction versus quantitative polymerase chain reaction for the detection of minimal residual disease in children with acute lymphoblastic leukemia.
Rev Bras Hematol Hemoter. 2015 Nov-Dec;37(6):366-8. doi: 10.1016/j.bjhh.2015.08.010. Epub 2015 Oct 9.
4
Rheumatic symptoms in childhood leukaemia and lymphoma-a ten-year retrospective study.
Pediatr Rheumatol Online J. 2013 May 4;11:20. doi: 10.1186/1546-0096-11-20. eCollection 2013.
5
The glucocorticoid receptor gene polymorphism N363S predisposes to more severe toxic side effects during pediatric acute lymphoblastic leukemia (ALL) therapy.
Int J Hematol. 2013 Feb;97(2):216-22. doi: 10.1007/s12185-012-1236-1. Epub 2013 Jan 26.
本文引用的文献
1
A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
Haematologica. 2009 Jun;94(6):781-9. doi: 10.3324/haematol.2008.003137.
2
Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.
Haematologica. 2009 Jun;94(6):870-4. doi: 10.3324/haematol.2008.000414. Epub 2009 Apr 18.
3
Molecular determinants of treatment response in acute lymphoblastic leukemia.
Hematology Am Soc Hematol Educ Program. 2008:366-73. doi: 10.1182/asheducation-2008.1.366.
4
Treatment of pediatric acute lymphoblastic leukemia.
Haematologica. 2008 Aug;93(8):1124-8. doi: 10.3324/haematol.13517.
5
Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible.
Cytometry B Clin Cytom. 2008 Nov;74(6):331-40. doi: 10.1002/cyto.b.20430.
6
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
Blood. 2008 May 1;111(9):4477-89. doi: 10.1182/blood-2007-09-112920. Epub 2008 Feb 19.
7
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
Leukemia. 2008 Apr;22(4):771-82. doi: 10.1038/leu.2008.5. Epub 2008 Jan 31.
8
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
Leukemia. 2007 Apr;21(4):604-11. doi: 10.1038/sj.leu.2404586. Epub 2007 Feb 8.
9
A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome.
Blood. 2006 Jul 1;108(1):97-102. doi: 10.1182/blood-2006-01-0066. Epub 2006 Mar 14.
10
Treatment of acute lymphoblastic leukemia.
N Engl J Med. 2006 Jan 12;354(2):166-78. doi: 10.1056/NEJMra052603.
Zotero 插件